Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call March 5, 2026 4:30 PM EST
Company Participants
Ioana Hone – Director of Investor Relations
Brian Culley – CEO, President & Director
Jill Howe – CFO & Principal Financial and Accounting Officer
Conference Call Participants
Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division
Jack Allen – Robert W. Baird & Co. Incorporated, Research Division
Mayank Mamtani – B. Riley Securities, Inc., Research Division
Gum-Ming Lowe – Craig-Hallum Capital Group LLC, Research Division
Yang Chen – Raymond James & Associates, Inc., Research Division
Presentation
Operator
Welcome to the Lineage Cell Therapeutics Third (sic) [ Fourth ] Quarter 2025 Conference Call. [Operator Instructions] An audio webcast of this call is available on the Investors section of Lineage’s website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage. And recordings, reproductions or transmission of this call without the expressed written consent of Lineage are strictly prohibited. As a reminder, today’s call is being recorded.
I would now like to introduce your host for today’s call, Ioana Hone, Head of Investor Relations at Lineage. Ms. Hone, please go ahead.
Ioana Hone
Director of Investor Relations
Thank you, Jamie. Good afternoon, and thank you for joining us. A press release reporting our fourth quarter and full year 2025 financial results was issued earlier today, March 5, 2026, and can be found on the Investors section of our website.
Please note that today’s remarks and responses to your questions reflect management’s views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties. The company’s actual results or performance may differ materially from the expectations indicated by









